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Abstract
Introduction: There is conflicting evidence and practice regarding the use of the non-nucleoside reverse transcriptase
inhibitors (NNRTI) efavirenz (EFV) and nevirapine (NVP) in first-line antiretroviral therapy (ART).
Methods: We systematically reviewed virological outcomes in HIV-1 infected, treatment-naive patients on regimens
containing EFV versus NVP from randomised trials and observational cohort studies. Data sources include PubMed, Embase,
the Cochrane Central Register of Controlled Trials and conference proceedings of the International AIDS Society, Conference
on Retroviruses and Opportunistic Infections, between 1996 to May 2013. Relative risks (RR) and 95% confidence intervals
were synthesized using random-effects meta-analysis. Heterogeneity was assessed using the I2 statistic, and subgroup
analyses performed to assess the potential influence of study design, duration of follow up, location, and tuberculosis
treatment. Sensitivity analyses explored the potential influence of different dosages of NVP and different viral load
thresholds.
Results: Of 5011 citations retrieved, 38 reports of studies comprising 114 391 patients were included for review. EFV was
significantly less likely than NVP to lead to virologic failure in both trials (RR 0.85 [0.73–0.99] I2 = 0%) and observational
studies (RR 0.65 [0.59–0.71] I2 = 54%). EFV was more likely to achieve virologic success than NVP, though marginally
significant, in both randomised controlled trials (RR 1.04 [1.00–1.08] I2 = 0%) and observational studies (RR 1.06 [1.00–1.12]
I2 = 68%).
Conclusion: EFV-based first line ART is significantly less likely to lead to virologic failure compared to NVP-based ART. This
finding supports the use of EFV as the preferred NNRTI in first-line treatment regimen for HIV treatment, particularly in
resource limited settings.
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Introduction
According to the 2010 World Health Organisation (WHO) HIV
treatment guidelines [1], the choice of non-nucleoside reverse
transcriptase inhibitor (NNRTI) for first-line antiretroviral therapy
(ART) for HIV-1 infected adults is either efavirenz (EFV) or
nevirapine (NVP), in combination with either zidovudine (AZT) or
tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC). In
contrast, the US Department of Health and Human Services [2]
and the International AIDS Society US guidelines [3] recommend
a preference for EFV over NVP for first-line therapy. More
recently, WHO has recommended that EFV should be considered
as the preferred first-line NNRTI [4]. A previous Cochrane review
concluded that there was no difference in efficacy between the two
drugs but found a higher risk of acquired resistance for patients on
NVP [5]. This finding was dominated by the large 2NN Study
comparing NVP and EFV regimens that found no difference in
efficacy between the two drugs [6]. A more recent review
comparing the use of these drugs specifically with TDF-containing
regimens concluded that EFV had superior virological efficacy [7].
In order to provide evidence in support of future regimen
choice, this systematic review provides an updated assessment of
the evidence regarding comparative efficacy of these two NNRTI
drugs as part of first-line antiretroviral therapy.
Methods
Criteria for Considering Studies for this Review
Types of studies. This review considers both experimental
and epidemiological study designs, including randomized con-
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trolled trials (RCTs), non-randomised controlled trials, quasi-
experimental, before and after studies, prospective, retrospective
and comparative cohort studies, and analytical cross-sectional
studies for inclusion.
Types of participants. This review considered studies that
included HIV-1 infected individuals who have not been previously
exposed to combination ART. For studies that include participants
irrespective of previous exposure, only data from ART-naive
patients were extracted. Exclusions included pregnant women,
ART experienced patients, virological failure (rebound) in patients
previously suppressed, where no viral load measurements were
done, and studies with planned switching to EFV or NVP.
Type of interventions. This review included studies that
evaluated EFV as compared to NVP-containing regimens in a
combination of three antiretroviral drugs only. The triple drug
combination therapy must contain two NRTIs with either EFV or
NVP. If cohorts report on other drugs in combination with EFV or
NVP, or two NRTIs and a protease inhibitor, then only data for
combination ART of two NRTIs with NVP or EFV were
extracted.
Types of outcome measures. This review considers studies
that included the following outcome measures:
1. Primary Outcomes
Virologic outcomes: comparison using plasma HIV-1 RNA
levels as measure of efficacy. Success was defined as HIV-1 RNA
plasma levels less than a value (copies/ml) as defined by the
authors/studies. Failure was defined as HIV-1 RNA plasma levels
more than a value (copies/ml) specified by the authors/studies. If
several time points are reported, data from the last point of
analysis was used.
2. Secondary Outcomes
Treatment termination/discontinuation (any cause) and mor-
tality were sought.
Search Strategy
(See Table S1 for details of search strategy).
A preliminary search of PubMed and Embase was undertaken
to identify key text words contained in the titles and abstracts of
relevant articles, and of the index terms used to describe an article.
A second search, using all identified keywords and index terms,
was then undertaken across the following databases: PubMed,
Embase and Cochrane Central Register of Controlled Trials
(Central). The bibliographies of all 139 full text reports and articles
were searched for additional studies. No language or geographical
restriction was applied. Finally, the abstract database of all
conferences of the International AIDS Society and the Conference
on Retroviruses and Opportunistic Infections was searched.
Studies published from January 1996 (the advent of triple
combination ART) to 01 May 2013 were considered for inclusion
in this review. All titles and abstracts were reviewed, duplicates
excluded and articles meeting the pre-defined inclusion criteria
were selected.
Data Extraction and Analysis
Data were extracted into pre-piloted Microsoft Excel tables and
included details about the interventions, populations, study
methods and outcomes of significance. Key outcome data
extractions were verified by duplicate extraction. Data analysis
was conducted using RevMan version 5.0 [8]. Papers selected for
review were assessed for risk of bias according to the following
criteria: random sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants and person-
nel (performance bias), blinding of outcome assessment (detection
bias), selective reporting (reporting bias),comparability of baseline
groups, application of intent-to-treat analysis, and proportion lost-
to follow up (see Table S2). Quality assessment on design of study,
risk of bias, inconsistency, indirectness and imprecision were
assessed using the GRADE framework [9] (www.
gradeworkinggroup.org). Where sufficient studies were available,
publication bias was assessed visually using funnel plots.
Relative risks (RR) for primary and secondary outcomes were
calculated on an intent-to-treat basis and pooled using random
effects meta-analysis. Where statistical pooling was not possible or
deemed inappropriate, study-specific outcomes are presented.
Heterogeneity was examined using the x2 statistic with a
significance level of .0.10, and the I2 statistic with an I2 estimate
greater than 50% was considered indicative of moderate to high
levels of heterogeneity [10]. The DerSimonian-Laird random-
effects method was used to recognize and anchor studies as a
sample of all potential studies, and to incorporate an additional
between-study component to the estimate of variability. If
significant statistical heterogeneity was found, and where feasible,
subgroup analyses were done to explore differences in outcomes
according to study design, duration of follow up, virological failure
or success as reported by the studies, studies for patients on
tuberculosis (TB) treatment, and study setting. Sensitivity analysis
explored the potential influence of NVP dosing schedule (200 mg
twice daily and 400 mg once daily) and differing thresholds of
virologic failure.
Results
Description of Studies
The search yielded 4990 abstracts, with 21 additional articles
identified from references of key articles. One hundred and thirty
nine articles were reviewed in full and 38 were included in the final
analysis (Fig. 1). In total, this review includes virologic outcome
data from 114,391 HIV-I-infected, combination ART-naive
patients from 27 countries. Most of the virological outcome data
are from high-income resource-rich settings and only eleven
published papers reported data from resource-limited settings
(South Africa, Nigeria, Senegal, Zambia, Botswana, Zimbabwe,
Uganda, Thailand, Mozambique, Burkina Faso and India). The
final included studies comprised of 10 randomised trials (data from
11 articles with additional long term data on the 2NN study [6]
from a second publication [11]); 15 prospective cohorts and 13
retrospective cohorts. One RCT [12] also reported on a non-
randomised cohort, but this cohort was not included as the
outcomes were not disaggregated by the NRTI backbone.
RCTs contributed 2% of total patient data, prospective cohort
studies contributed 57% of data, and the remainder (41%) came
from retrospective cohorts. In total, 63% of patients were on EFV.
The majority of studies compared EFV 600 mg once daily
against NVP 200 mg twice daily. One study adjusted EFV dose to
weight [13], and two studies used NVP 400 mg once daily [14,15].
Fifteen studies did not report NVP dosage, and were all assumed
to use 200 mg twice daily as this is the standard recommended
dosage [1].
NRTI backbones used differed between studies. Stavudine
(d4T)/3TC were used in 21 studies and 9 studies did not use this
NRTI backbone at all. AZT/3TC was used in 21 studies and 9
studies did not use this backbone at all. TDF/3TC or TDF/FTC
was used less frequently, in only 7 studies. Seven studies did not
report on NRTI backbones used.
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Sample sizes ranged from 50 patients [16] to .27,000 patients
[17]. Over half of all studies (n = 20) were published after 2008.
Overall, more females were likely to be on NVP as EFV use has,
until recently, been contra-indicated in pregnancy [18]. Only one
study, the HIV-CAUSAL collaboration [19], excluded those with
AIDS-defining illness. Baseline characteristics are summarized in
Table 1.
Six studies were done exclusively in TB/HIV co-infected
patients [13,20,21,22,23,24]. Another study included 188 patients
on EFV and 86 patients on NVP who were co-infected with TB
[25] while 36.1% of the IeDEA cohort [17] and 6.7% of the
Kheth’Impilo cohort [26] were TB co-infected. These studies do
not report the virologic outcomes of those co-infected patients and
were thus not included in that subgroup meta-analysis.
Figure 1. Search strategy.
doi:10.1371/journal.pone.0068995.g001
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Risk of Bias and GRADE Assessment
The assessment of the overall quality of the studies is
summarised in Table S2. Only two trials reported on allocation
concealment [6,15], and all studies were open label. Three of the
randomised studies were partly or fully funded by the pharma-
ceutical industry [11,12,27], and this was disclosed in their
publications; the others did not report on their source of funding
(see Table S2). Two observational studies took a random selection
from the observational cohort for their analysis [23,25]. Only 13
studies (five of ten RCTs and eight observational cohorts) reported
loss to follow-up figures and all were below 20% (0.5% to 19.8%)
(Table S2).
The evidence from RCTs was considered to be high quality for
critical outcomes: there were no evidence of serious risk of bias,
inconsistency, imprecision or indirectness In contrast, the
evidences from observational studies was judged to be of very
low quality, mainly due to risk of bias (lack of random sampling,
baseline imbalances, and retrospective design), and inconsistency
in the direction and imprecision in the confidence intervals around
the point estimates. There were some well-designed prospective
cohort and collaborative cohort studies that were rated to be of
moderate quality, but this was not sufficient to upgrade the quality
of the observational data overall.
Publication bias was assessed by funnel plot (Fig. 2) and the
eggers test for small study effects; these analyses were limited to the
primary outcomes of virologic failure and success for observational
studies because there were too few RCTs to allow these analyses to
be performed. No significant bias was detected for either outcome
(p = 0.2).
Virologic Failure
Six RCTs (n = 1572) provided evidence for the primary
outcome of virologic failure. Overall, 16.7% on EFV and 20.7%
of NVP patients failed treatment (RR 0.85 [0.73– 0.99], I2 = 0%)
(Fig. 3). This result was consistent for the estimates derived by
pooling data from nine observational studies (n = 67483): 7% of
patients taking EFV versus 10.5% of those on NVP were observed
to have failed treatment (RR 0.65 [0.59–0.71]) (Fig. 3). There was
significant heterogeneity between studies (I2 = 54%), which was
largely explained by the inclusion of the large, combined cohorts
of IeDEA [17] and the HIV CAUSAL Collaboration [19].
Virologic Success
There was a marginal significance between the two drugs, with
EFV being more likely to achieve virological success compared to
NVP. Eight RCT (n = 2550) that measured virologic success (HIV-
1 RNA copies/ml less than a specified cut-off value) showed that
patients on EFV (73.7%) were more likely to achieve success than
those taking NVP (200 mg twice daily) (70.4%) with a pooled RR
of 1.04 [95%CI 1.00–1.08], and no heterogeneity between the
studies was observed (I2 = 0%) (Fig. 4). Observational studies that
reported on success (13 of 28; n = 14778) also reported better rates
of suppression; 63.7% for EFV versus 60.1% for NVP with a
pooled RR of 1.06 [1.00– 1.12] (Fig. 4). Heterogeneity was
moderate (I2 = 68%) and in subgroup analysis this appeared to be
largely explained by the inclusion of retrospective studies.
Four cohorts did not report data by number of events and thus
were not included in the meta-analysis but their findings are
consistent with the overall result. One study reported no difference
in virologic success between the two drugs (HR 1.37 [0.35–1.68]
[36]. Bock and colleagues reported that those on EFV were more
likely to suppress (,400copies/ml) (adjusted odds ratio 1.29 [1.05–
1.59]) [26]. Another study found that patients on NVP were more
likely to fail (adjusted hazards ratio 2.15 [0.90–5.13]) [28]. Finally,
a fourth study reported that virologic success at six months was
38% for NVP and 59% for EFV-based ART, although loss to
follow up in this study was highly differential (25% for NVP and
41% for EFV) [29].
Virologic Outcomes in HIV/TB Co-infected Patients
Six studies provided data on virologic success of TB/HIV co-
infected patients on TB treatment (n = 1187). Those on EFV and
TB treatment were no more likely to suppress than those on NVP
in three RCTs (RR = 1.06 [0.97– 1.17] = 0%) and in three
comparative cohort studies (RR 1.02 [0.70–1.47] I2-63%). Four
observational studies provided data on virologic failure with those
on EFV and TB treatment more likely to suppress than those on
NVP (RR 0.58 [0.34, 0.99] I2 = 78%).
Mortality
There was no significant difference noted in mortality rates in
four RCTs between the two NNRTI’s (n = 1067) (RR of 0.81
[0.47, 1.37] I2 = 30%). However, in the eight observational studies
that reported mortality (n = 45588), EFV was protective (RR 0.76
[0.67–0.87], I2 = 0%) compared to NVP (Fig. 5).
Treatment Discontinuation (any cause)
Date from five RCTs (n = 1648) showed no significant
difference between EFV and NVP in terms of discontinuation of
treatment due to any cause (RR 0.83 [0.55–1.25]). Similar results
were found in seven observational studies (RR = 0.89 [0.73–1.08])
with 27% in both NNRTI groups alike discontinuing treatment for
any reason. The majority of treatment discontinuations were
driven by adverse events.
Sensitivity Analysis
A sensitivity analysis was carried out to assess if the results of the
meta-analysis are robust depending on the different dosages of
NVP and differing threshold definitions of failure. The results
show no significant difference of the relative risk of an outcome
when EFV was compared strictly to studies of NVP 200 mg twice
daily [14,15], compared to studies regardless of NVP dosage
(Table S3).
Sensitivity analyses results of the meta-analysis, after excluding
studies that used a lower threshold and observing how this affected
the results, showed that the risk of failure for those taking NVP is
consistently much higher than EFV irrespective of different
thresholds in both RCTs and observational studies (Table S3).
Subgroup Analysis
Several subgroup analyses were performed to assess the
potential influence of study duration. For the outcome of
virological suppression, studies that ran to 24 weeks were found
to be non-significant (RR 1.15, 95% CI 0.89–1.50) although this is
likely due to small sample size as only 2 studies contributed to this
subgroup analysis; for 48 weeks, the results remained significant (8
studies: RR 1.04, 95%CI 1.00–1.08). In subgroup analyses of
different settings, patients on EFV compared to NVP in RCTs
were less likely to fail in resource-limited settings (RR 0.75 [0.60,
0.93] I2 = 0%) but not in resource-rich settings (RR 0.93 [0.77–
1.13] I2 = 24%) (Fig. 6).
Discussion
This systematic review found EFV was significantly less likely to
lead to virological failure than NVP. Although marginally
significant, EFV was also more likely to achieve virological success
than NVP. These findings were consistent across all study designs.
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Among TB/HIV co-infected patients, there was no difference in
viral suppression among those on EFV and TB treatment and
those taking NVP and TB treatment. Mortality appeared to be
lower among patients on EFV in observational studies, but this
was not seen in the RCTs.
Based on the large 2NN RCT [6], which found similar efficacy
between EFV and NVP to suppress HIV-1 levels below 50 copies/
Figure 2. Funnel Plots.
doi:10.1371/journal.pone.0068995.g002
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ml but significant differences in virologic failure by region, a
subgroup analysis was performed on RCTs comparing those
conducted within resource-limited settings to those conducted in
resource-rich settings. This analysis found that the benefit of EFV
over NVP was especially highlighted in resource-limited settings
when compared to resource-rich settings. This is important for
resource-limited settings where the smaller risk of EFV leading to
treatment failure has a critical effect in reducing the risk of
unnecessary switches to a more expensive second-line treatment.
Viral load measurements are not widely available in resource-
limited settings. The sensitivity analyses showed that regardless of
the threshold definition of virologic failure used, EFV consistently
proves to be a better option. If treatment aims for viral suppression
are to avoid the emergence of resistance, disease progression and
death, then patients should be initiated on a more robust, durable
first-line NNRTI such as EFV, especially in resource-limited
setting where alternative options are limited.
A previous systematic review compared 7 RCTs (1,688 patients)
of EFV and NVP use in treatment-naı¨ve individuals and found no
critical difference between the regimens [5]. This review includes
additional data from 3 further RCTs, and data from observational
studies which was able to assess outcomes among a total of 114
391 patients. Furthermore, we included updated, longer term
outcome reports from the largest RCT (the 2NN study [6,11]).
This review also limited all analyses to ART-naı¨ve patients and to
those who had two NRTIs as a backbone, in contrast to the
previous review which also included patients receiving protease-
inhibitor based therapy. Another recent review that assessed
comparative efficacy of EFV compared to other regimens also
found superior virologic suppression in favour of EFV-based
regimen [30]. Our review differed from this review by focusing
specifically on the NVP versus EFV studies, thereby including a
much larger dataset for this comparison.
There are several limitations to this review. First, we chose to
include observational data in order to assess a wider evidence base,
but observational studies are subject to unmeasured confounding.
To address these concerns we presented trial and observational
data separately, and undertook subgroup analyses to explore the
potential influence of study design on our primary outcome, and
no important differences were found. Second, differences in
virological outcomes may be partly explained by differences in
adherence between the groups because in some studies the EFV-
containing regimen was administered as a once-a-day regimen,
and EFV is associated with a lower overall frequency of adverse
Figure 3. Outcome virologic failure in RCTs and observational studies.
doi:10.1371/journal.pone.0068995.g003
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events [31]; both of these issues are associated with improved
adherence. However, while once-daily dosing improves adherence
the overall effect on virologic suppression is unclear [32], and in
this review studies that have adjusted for adherence still found a
better virological response with EFV [33,34,35]. As with any
systematic review, another limitation is publication bias. Attempts
were made to limit the possibility of having missed studies by
including conference abstracts, and trying to contact authors for
more information, and there was no statistical evidence of
publication bias. Differential LTFU between intervention groups
is an important source of bias. This was poorly reported by studies,
but in 6 studies where LTFU was reported by drug, this appeared
to be non-differential. Lastly, we could not explore the potential
influence of differing NRTI backbones as too few studies provided
data of outcomes by backbone that were not already accounted for
in two previously published reviews [5,7]. The Cochrane review
reported that both EFV and NVP have demonstrated clinical
efficacy largely with patients on a d4T/3TC NRTI backbone [5],
the majority of whom were drawn from the 2NN study [6].
However, a more recent meta-analysis showed that even with
newer regimens containing TDF, NVP was inferior to EFV [7].
Future studies are encouraged to report data for both treatment
success and failure, using internationally agreed definitions, and
important secondary outcomes.
In conclusion, the findings of this review as well as recent
recommendations to use EFV in the first trimester of pregnancy
[4,36], its improved toxicity profile [31], and improved cost-
effectiveness resulting from recent EFV price reductions [37]; all
support recommendations preferring the use of a once daily fixed-
dose combination of TDF/3TC/EFV.
Figure 4. Outcome virologic success in RCTs and observational studies.
doi:10.1371/journal.pone.0068995.g004
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Figure 5. Outcome mortality in RCTs and observational studies.
doi:10.1371/journal.pone.0068995.g005
Figure 6. Outcome virologic failure in RCTs-subgroups by settings.
doi:10.1371/journal.pone.0068995.g006
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